Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000296036 encodes a long non-coding RNA transcript that is transcribed antisense to the MGMT locus. Antisense lncRNAs can affect the expression and stability of their overlapping protein-coding genes, often through modulation of local chromatin state or by directly interacting with the partner mRNA. For many such antisense RNAs, including those near critical genes like MGMT, emerging research indicates a potential regulatory role in gene expression, potentially influencing response to chemotherapy in cancers such as glioma; however, there is no established therapeutic targeting of this transcript, nor validated disease associations specific to this lncRNA aside from its genomic position and putative regulatory potential.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to MGMT.